why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 185 result(s) (Page 1 of 19)
Drug Name: Mimrylo

Active Ingredient: rusfertide

Approval Date: 2026-08-28

Description: To treat erythrocytosis in adults with polycythemia vera

Drug Name: Lisraya

Active Ingredient: brepocitinib

Approval Date: 2026-08-27

Description: To treat dermatomyositis in adults

Drug Name: Rasonque

Active Ingredient: daraxonrasib

Approval Date: 2026-08-26

Description: To treat metastatic pancreatic cancer

Drug Name: Pasatru

Active Ingredient: garetosmab-grts

Approval Date: 2026-08-19

Description: To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

Drug Name: Tauklarify

Active Ingredient: florquinitau F 18

Approval Date: 2026-08-13

Description: To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

Drug Name: Zenbexus

Active Ingredient: iberdomide

Approval Date: 2026-08-13

Description: To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

Drug Name: Orzeyful

Active Ingredient: oveporexton

Approval Date: 2026-08-05

Description: To treat narcolepsy type 1

Drug Name: Lytenava

Active Ingredient: bevacizumab-vikg

Approval Date: 2026-07-24

Description: To treat patients with neovascular (wet) age-related macular degeneration

Drug Name: Simtriyo

Active Ingredient: centanafadine

Approval Date: 2026-07-24

Description: To treat attention-deficit hyperactivity disorder

Drug Name: Jideytro

Active Ingredient: zidesamtinib

Approval Date: 2026-07-22

Description: To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

300×250 Ad Slot